Cryo-Cell International I... (CCEL)
Cryo-Cell International Statistics
Share Statistics
Cryo-Cell International has 8.5M shares outstanding. The number of shares has increased by -0.28% in one year.
Shares Outstanding | 8.5M |
Shares Change (YoY) | -0.28% |
Shares Change (QoQ) | 0.25% |
Owned by Institutions (%) | 12.79% |
Shares Floating | 4.43M |
Failed to Deliver (FTD) Shares | 2 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 6.3K, so 0.08% of the outstanding shares have been sold short.
Short Interest | 6.3K |
Short % of Shares Out | 0.08% |
Short % of Float | 0.12% |
Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 175.31 and the forward PE ratio is -536.14. Cryo-Cell International's PEG ratio is -1.68.
PE Ratio | 175.31 |
Forward PE | -536.14 |
PS Ratio | 2.2 |
Forward PS | 1.4 |
PB Ratio | -5.33 |
P/FCF Ratio | 19.54 |
PEG Ratio | -1.68 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cryo-Cell International.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.58, with a Debt / Equity ratio of -0.34.
Current Ratio | 0.58 |
Quick Ratio | 0.55 |
Debt / Equity | -0.34 |
Debt / EBITDA | 3.13 |
Debt / FCF | 1.23 |
Interest Coverage | 1.87 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $390.07K |
Profits Per Employee | $4.9K |
Employee Count | 82 |
Asset Turnover | 0.49 |
Inventory Turnover | 12.08 |
Taxes
Income Tax | 2.4M |
Effective Tax Rate | 85.66% |
Stock Price Statistics
The stock price has increased by -39.09% in the last 52 weeks. The beta is 0.69, so Cryo-Cell International's price volatility has been higher than the market average.
Beta | 0.69 |
52-Week Price Change | -39.09% |
50-Day Moving Average | 6.33 |
200-Day Moving Average | 7.05 |
Relative Strength Index (RSI) | 34.93 |
Average Volume (20 Days) | 15.54K |
Income Statement
In the last 12 months, Cryo-Cell International had revenue of 31.99M and earned 402.1K in profits. Earnings per share was 0.05.
Revenue | 31.99M |
Gross Profit | 24.04M |
Operating Income | 3.48M |
Net Income | 402.1K |
EBITDA | 1.42M |
EBIT | 939.44K |
Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 560.96K in cash and 4.45M in debt, giving a net cash position of -3.89M.
Cash & Cash Equivalents | 560.96K |
Total Debt | 4.45M |
Net Cash | -3.89M |
Retained Earnings | -32.78M |
Total Assets | 64.38M |
Working Capital | -9.21M |
Cash Flow
In the last 12 months, operating cash flow was 6.01M and capital expenditures -2.4M, giving a free cash flow of 3.61M.
Operating Cash Flow | 6.01M |
Capital Expenditures | -2.4M |
Free Cash Flow | 3.61M |
FCF Per Share | 0.44 |
Margins
Gross margin is 75.15%, with operating and profit margins of 10.88% and 1.26%.
Gross Margin | 75.15% |
Operating Margin | 10.88% |
Pretax Margin | 8.77% |
Profit Margin | 1.26% |
EBITDA Margin | 4.45% |
EBIT Margin | 10.88% |
FCF Margin | 11.28% |
Dividends & Yields
CCEL does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for CCEL is $8.5, which is 62.8% higher than the current price. The consensus rating is "Buy".
Price Target | $8.5 |
Price Target Difference | 62.8% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Scores
Altman Z-Score | 0.06 |
Piotroski F-Score | 9 |